Takeda has announced a new partnership with the Karolinska Institutet and the Structural Genomics Consortium (SGC) in the field of inflammatory bowel disease (IBD).
The combined pre-competitive and proprietary collaboration aims to discover and validate new potential intervention points for the treatment of IBD, with a joint translational medicine research team of scientists and clinicians set to be established.
“Takeda is allying with the Karolinska Institutet and the Structural Genomics Consortium to develop new approaches to treating inflammatory bowel disease.“
Their work will focus on the development of advanced translational disease models from patient-derived tissue samples from a large and well-characterised IBD patient cohort, with these assays used to test high-quality chemical probes from the SGC and compounds from Takeda.
By doing so, the scientific team will be able to gain new insights into previously unexplored cellular targets and pathways spanning a number of diseases where substantial unmet needs exist, including ulcerative colitis and Crohn's disease.
Dr Gareth Hicks, head of the gastrointestinal drug discovery unit at Takeda, said: "Our partnership with scientists at the Karolinska Institutet and the SGC is a critical element of our effort toward discovering and assessing new approaches to the treatment of IBD."
With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Pharmaceutical